Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

BACKGROUND: The benefit of apixaban to reduce stroke risk in morbidly obese patients with nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of Thrombosis and Hemostasis recommends avoiding the use of direct oral anticoagulants (DOAC)s in morbidly obese patients (b...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Sulaiman, Khalid, Badreldin, Hisham A., Korayem, Ghazwa B., Alenazi, Abeer A., Alsuwayyid, Faisal, Alrashidi, Abdulrahman, Alhijris, Mohammed, Almutairi, Faisal, Alharthi, Fahad, Vishwakarma, Ramesh, Al Shaya, Omar, Al Amri, Abdulrahman, Tayyab, Saqiba, Al Bekairy, Abdulkareem M., Aljuhani, Ohoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063081/
https://www.ncbi.nlm.nih.gov/pubmed/35501916
http://dx.doi.org/10.1186/s12959-022-00379-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063081/
https://www.ncbi.nlm.nih.gov/pubmed/35501916
http://dx.doi.org/10.1186/s12959-022-00379-x

Ejemplares similares